NEWS
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm
Aptevo Therapeutics (NASDAQ:APVO)provided updates on its oncology pipeline focusing on bispecific antibodies for cancer treatment. The company highlighted two clinical programs: mipletamig for AML, which showed 90% reduction in leukemic blasts in its first Phase 1b/2 trial patient, and ALG.APV-527for solid tumors, which demonstrated positive safety and 56% stable disease rate in Phase 1. The pipeline includes three preclinical candidates: APVO711, APVO603, and APVO442. The company expects the bispecifics market to grow by 44% through 2030 and plans to add another asset to its pipeline soon.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2874Followers
108Following
30KVisitors
Follow